[go: up one dir, main page]

AR031924A1 - ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE - Google Patents

ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE

Info

Publication number
AR031924A1
AR031924A1 ARP010105828A ARP010105828A AR031924A1 AR 031924 A1 AR031924 A1 AR 031924A1 AR P010105828 A ARP010105828 A AR P010105828A AR P010105828 A ARP010105828 A AR P010105828A AR 031924 A1 AR031924 A1 AR 031924A1
Authority
AR
Argentina
Prior art keywords
antibodies
silenced
methods
tissues
defective
Prior art date
Application number
ARP010105828A
Other languages
Spanish (es)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR031924A1 publication Critical patent/AR031924A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion provee anticuerpos anti-CD28 que son defectuosos en actividad mitogeno (anticuerpos anti-CD28 silenciados), métodos para producir dichos anticuerpos, composiciones que contienen anticuerpos y métodos de inmunosupresion, inducen tolerancia de células T y tratan rechazos de transplantes de organos y/o tejidosThe present invention provides anti-CD28 antibodies that are defective in mitogenic activity (silenced anti-CD28 antibodies), methods for producing said antibodies, compositions containing antibodies and immunosuppression methods, induce tolerance of T cells and treat organ transplant rejections and / or tissues

ARP010105828A 2000-12-14 2001-12-14 ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE AR031924A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
AR031924A1 true AR031924A1 (en) 2003-10-08

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105828A AR031924A1 (en) 2000-12-14 2001-12-14 ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE

Country Status (18)

Country Link
EP (1) EP1341553A4 (en)
JP (1) JP2004515243A (en)
KR (1) KR20040020866A (en)
CN (1) CN1272345C (en)
AR (1) AR031924A1 (en)
AU (2) AU2608602A (en)
BR (1) BR0116686A (en)
CA (1) CA2432736A1 (en)
CZ (1) CZ20031909A3 (en)
HU (1) HUP0400697A3 (en)
IL (1) IL156262A0 (en)
MX (1) MXPA03005327A (en)
NO (1) NO20032542L (en)
NZ (1) NZ526569A (en)
PL (1) PL363239A1 (en)
RU (1) RU2261723C2 (en)
WO (1) WO2002047721A1 (en)
ZA (1) ZA200305384B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
ES2776657T3 (en) 2005-06-14 2020-07-31 Amgen Inc Self-buffering protein formulations
FR2951176A1 (en) 2009-10-09 2011-04-15 Tcl Pharma MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
ES2896149T3 (en) * 2010-02-18 2022-02-24 Ose Immunotherapeutics Humanized anti-CD28 antibodies
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
KR20230166150A (en) 2020-08-19 2023-12-06 젠코어 인코포레이티드 Anti-cd28 compositions
JP2024512669A (en) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Tanotransmission polypeptides and their use in the treatment of cancer
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
CA3252619A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521288A (en) * 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein

Also Published As

Publication number Publication date
MXPA03005327A (en) 2004-12-03
JP2004515243A (en) 2004-05-27
RU2261723C2 (en) 2005-10-10
NZ526569A (en) 2005-07-29
CA2432736A1 (en) 2002-06-20
RU2003121231A (en) 2005-02-10
NO20032542D0 (en) 2003-06-05
CN1489473A (en) 2004-04-14
HUP0400697A3 (en) 2007-05-02
WO2002047721A1 (en) 2002-06-20
NO20032542L (en) 2003-08-07
EP1341553A1 (en) 2003-09-10
KR20040020866A (en) 2004-03-09
HUP0400697A2 (en) 2004-06-28
BR0116686A (en) 2003-12-30
AU2002226086B2 (en) 2005-08-25
EP1341553A4 (en) 2004-07-28
IL156262A0 (en) 2004-01-04
CN1272345C (en) 2006-08-30
AU2608602A (en) 2002-06-24
PL363239A1 (en) 2004-11-15
CZ20031909A3 (en) 2003-11-12
AU2002226086C1 (en) 2006-03-09
ZA200305384B (en) 2004-10-11

Similar Documents

Publication Publication Date Title
AR031924A1 (en) ANTI-CD28 SILENCED ANTIBODIES AND THE USE OF THESE
MX2009003588A (en) Human placental collagen compositions, and methods of making and using the same.
ES2183937T3 (en) INHIBITORS OF THE CELL ADHESION.
ES2157994T3 (en) TETRA INHIBITORS AND SUBSTITUTED PENTAPEPTIDES OF THE PROTEIN FARNESILTRANSFERASA.
ECSP088298A (en) MODULATION OF GLUCOCORTICOID RECEIVER EXPRESSION
AR023463A1 (en) USE OF AZETIDINONE COMPOUNDS
MXPA03001389A (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF MALIGNITIES ASSOCIATED WITH HER-2 / NEU.
UY24256A1 (en) SPECIFIC MONOCLONAL MONO ANTIBODIES FOR HUMAN B 7.1 AND / OR B7.2 ANTIBODIES, PRIMATIZED FORMS OF THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME AS IMMUNOSUPPRESSORS
BR0114630A (en) Growth Hormone Secretagogues
ECSP045520A (en) TREATMENT METHODS WITH PTEC INHIBITORS AND ANTIHIPERTENSIVE AGENTS
GT200300031A (en) SUBSTITUTE INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
ATE529125T1 (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR ACCELERATING WOUND HEALING
CY1109413T1 (en) METHODS OF TREATMENT OF MULTIPLE MYELOMA AND BACKGROUND OF BONE REPLACEMENT BY USING INTEGRE
BR0214029A (en) Methods and compositions for using stromal cells to support embryonic and adult stem cells
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
ECSP045146A (en) SMALL MOLECULES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
DE69721021D1 (en) BUBBLE MUKOSA WITH CELLS FOR TISSUE RECONSTRUCTION
ATE526991T1 (en) COMPOSITIONS AND THEIR USES FOR THE GENETHERAPEUTIC TREATMENT OF BONE DISEASES
PA8650801A1 (en) COMPOSITIONS AND FORMULATIONS OF ECTEINASCIDINE, LIKE ECTEINASCIDINE 743
AR052447A1 (en) 1- (2-METIPROPIL) ETANSULFONATE -1H-IMIDAZO [4,5-C] [1,5] NAFTIRIDIN-4- AMINA AND 1- (2- METIPROPIL) -1H-IMIDAZO [4,5-C ] [1,5] NAFTIRIDIN-4-AMINA
CO2024005352A2 (en) Oligonucleotide compositions and methods thereof
GT200300046A (en) INDOLIL-UREA DERIVED FROM USEFUL TIENOPIRIDINS AS ANTIANGIOGEN AGENTS AND PROCEDURES FOR USE
BR0307629A (en) Methods and compositions for treating hyperproliferative conditions
BRPI0607883A2 (en) method for obtaining readily available peripheral blood derived cellular material and a composition of said cellular material
BR0314369A (en) Methods for inhibiting cell growth, for inducing cell death of a cancer cell, for treating or preventing cancer in an individual, and for identifying an agent that inhibits cancerous growth of a purified ephb4 cell, agent, and antibody.

Legal Events

Date Code Title Description
FB Suspension of granting procedure